Tags

Type your tag names separated by a space and hit enter

Indirect treatment comparison of valbenazine and deutetrabenazine efficacy and safety in tardive dyskinesia.
J Comp Eff Res 2019; 8(13):1077-1088JC

Abstract

Aim:

Utilize the Bucher indirect treatment comparison (ITC) method to compare valbenazine and deutetrabenazine efficacy using clinical trial data.

Methods:

Outcomes included mean change from baseline in Abnormal Involuntary Movement Scale (AIMS) total score, AIMS response (≥50% improvement), clinical global impression of change response (score ≤2) and safety outcomes. Data were pooled by trial and dose; outcomes were analyzed at multiple time points.

Results:

ITC of AIMS score improvement significantly favored valbenazine 80 mg/day at 6 weeks versus deutetrabenazine 36 mg/day at 8 weeks, while valbenazine 40 mg/day was statistically similar to all doses of deutetrabenazine at all time points. No significant differences between drugs were found in AIMS and clinical global impression of change responses and safety outcomes.

Conclusion:

In this ITC of pooled trial data, valbenazine was generally favorable over deutetrabenazine, although dose titration and equivalency should be considered when interpreting results.

Authors+Show Affiliations

Novel Health Strategies, Columbia, MD 21044, USA.Neurocrine Biosciences, Inc., San Diego, CA 92130, USA.Neurocrine Biosciences, Inc., San Diego, CA 92130, USA.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31464152

Citation

Aggarwal, Saurabh, et al. "Indirect Treatment Comparison of Valbenazine and Deutetrabenazine Efficacy and Safety in Tardive Dyskinesia." Journal of Comparative Effectiveness Research, vol. 8, no. 13, 2019, pp. 1077-1088.
Aggarwal S, Serbin M, Yonan C. Indirect treatment comparison of valbenazine and deutetrabenazine efficacy and safety in tardive dyskinesia. J Comp Eff Res. 2019;8(13):1077-1088.
Aggarwal, S., Serbin, M., & Yonan, C. (2019). Indirect treatment comparison of valbenazine and deutetrabenazine efficacy and safety in tardive dyskinesia. Journal of Comparative Effectiveness Research, 8(13), pp. 1077-1088. doi:10.2217/cer-2019-0059.
Aggarwal S, Serbin M, Yonan C. Indirect Treatment Comparison of Valbenazine and Deutetrabenazine Efficacy and Safety in Tardive Dyskinesia. J Comp Eff Res. 2019;8(13):1077-1088. PubMed PMID: 31464152.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Indirect treatment comparison of valbenazine and deutetrabenazine efficacy and safety in tardive dyskinesia. AU - Aggarwal,Saurabh, AU - Serbin,Michael, AU - Yonan,Chuck, Y1 - 2019/08/29/ PY - 2019/8/30/pubmed PY - 2019/8/30/medline PY - 2019/8/30/entrez KW - deutetrabenazine KW - efficacy KW - indirect treatment comparison KW - tardive dyskinesia KW - valbenazine SP - 1077 EP - 1088 JF - Journal of comparative effectiveness research JO - J Comp Eff Res VL - 8 IS - 13 N2 - Aim: Utilize the Bucher indirect treatment comparison (ITC) method to compare valbenazine and deutetrabenazine efficacy using clinical trial data. Methods: Outcomes included mean change from baseline in Abnormal Involuntary Movement Scale (AIMS) total score, AIMS response (≥50% improvement), clinical global impression of change response (score ≤2) and safety outcomes. Data were pooled by trial and dose; outcomes were analyzed at multiple time points. Results: ITC of AIMS score improvement significantly favored valbenazine 80 mg/day at 6 weeks versus deutetrabenazine 36 mg/day at 8 weeks, while valbenazine 40 mg/day was statistically similar to all doses of deutetrabenazine at all time points. No significant differences between drugs were found in AIMS and clinical global impression of change responses and safety outcomes. Conclusion: In this ITC of pooled trial data, valbenazine was generally favorable over deutetrabenazine, although dose titration and equivalency should be considered when interpreting results. SN - 2042-6313 UR - https://www.unboundmedicine.com/medline/citation/31464152/Indirect_treatment_comparison_of_valbenazine_and_deutetrabenazine_efficacy_and_safety_in_tardive_dyskinesia L2 - http://www.futuremedicine.com/doi/full/10.2217/cer-2019-0059?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -